The assay is the easy part

Running a PGx panel is a solved problem for most CLIA laboratories. The moment you have to interpret the result, though, the scope explodes. A single star-allele call has to be mapped to a phenotype, matched against every relevant drug, graded on current evidence, and rendered into something a prescriber can act on. That interpretation layer is the real product — and it never stops needing work.

Building in-house means owning a permanent evidence pipeline. You have to curate and reconcile CPIC guidelines, FDA pharmacogenomic biomarker labeling, DailyMed prescribing data, and DPWG recommendations across dozens of genes and hundreds of drugs — then keep that graph accurate every time a source is revised.

The cost that isn’t on the quote

The build estimate people write down covers software. The cost that actually hurts is ongoing: the scientific and medical labor required to keep interpretations correct month after month, long after the initial system ships.

A credible in-house program has to permanently staff three standing functions, so the real budget covers:

• curation

• review

• software

Every one of those is a standing line item, not a one-time build cost — and each carries clinical liability if it lapses.

Guidelines move, and so do patients

PGx evidence is not static. CPIC revises guidelines, the FDA updates label language, and new gene-drug pairs reach actionable status. A report that was correct at sign-out can quietly drift out of date.

Handling that in-house means building surveillance for every source, a way to detect which past reports are affected, and a workflow to route those cases back to a medical director for re-review. Most labs discover this requirement only after the first guideline change leaves older reports stale.

Someone still has to sign it out

A PGx report is a clinical document. However the interpretation is generated, a qualified medical director has to review and sign out the result — and that review has to be fast enough not to bottleneck turnaround.

In-house, that means designing an assisted-review workflow where automation flags gene-drug interactions but a clinician always makes the call. Building that balance — enough automation to scale, never so much that software decides — is its own engineering and compliance project.

Delivery is where it gets real

A PDF emailed to a physician is not a reporting program. Real adoption depends on results landing inside the systems clinicians already use.

That means FHIR R4, HL7 ORU, CDS Hooks, and SMART on FHIR — plus patient-facing access.

Each interface is a standard with its own conformance, versioning, and testing burden, and every EHR connection has to be built and maintained. Underneath it all sits multi-tenant security: HIPAA and GDPR compliance, encryption in transit and at rest, RBAC, strict tenant isolation, and a full audit trail.

decision = model.predict(input_data)
execute(decision)

What a turnkey platform removes

A white-label platform like SignalPGx exists so a lab doesn’t have to rebuild any of that. The lab runs the genotyping; SignalPGx turns VCF, CSV, Agena MassARRAY, or array results into branded, physician-reviewed reports delivered into the EHR.

The recurring work you would otherwise own is absorbed, including:

1. the multi-source evidence pipeline

2. guideline and medication surveillance

3. standards-based EHR delivery

Evidence is graded against CPIC, FDA labeling, DailyMed, and DPWG across roughly 50 pharmacogenes and about 950 medications, reconciled from more than 15 curated sources. SignalAI assists interpretation and flags gene-drug interactions, but your medical director reviews and signs out every report. Living Reports re-analyze automatically when guidelines or a patient’s medications change, routing flagged cases back for a fresh medical-director review.

Conclusion

The build question is rarely “can we?” — it’s “can we keep doing it, correctly, forever?”

For most labs, buying converts a permanent scientific, clinical, and engineering commitment into transparent per-report pricing and a live program in about a week. SignalPGx is not a diagnostic test and never replaces the physician — final prescribing stays with the ordering clinician — but it removes the hidden, ongoing cost of doing PGx reporting well.